PHARMACOECONOMIC ANALYSIS OF THE USE OF COMBINATION PENTAXIM ® VACCINE UNDER THE NATIONAL IMMUNIZATION SCHEDULE OF THE RUSSIAN FEDERATION

The article assesses the economic impact of inclusion of combination Pentaxim 9 vaccine in the immunization schedule for infants aged 0 to 18 months to increase Haemophilus influenzae type b (HIB) infection vaccination coverage from 12 to 95% and to reduce its burden; to turn to primary vaccination and first revaccination with inactivated polio vaccine (IPV) instead of live oral polio vaccine and to eliminate vaccine-associated poliomyelitis; to switch from whole-cell pertussis-diphtheria-tetanus (DwTP) vaccine to less reactogenic combination DTaP (diphtheria-tetanus toxoid adsorbed-acellular pertussis)/IPV/conjugated HIB vaccine, and to reduce the number of injections in the immunization schedule for babies. Pharmacoeconomic analysis has shown that it is expedient to introduce Pentaxim ® vaccine in the Russian national immunization schedule for children. Incremental cost-effectiveness analysis and cost-utility analysis have indicated that Scenario 1 comprising 4 injections of combination Pentaxim ® vaccine is dominant (strictly preferential) from the standpoint of the state and highly cost-effective (more preferential than the current scenario) from the perspective of the health care system. Budget impact analysis has shown that switching from the current vaccination scheme to the combination vaccine one in term of expenditures on the healthcare system only will require additional cash flow, but, with allowance made for the social and other expenses outside the budget of the health care system, permit the monetary resources of the state to be saved.

Pentaxim, pharmacoeconomics, vaccination, pediatric combination vaccines, Haemophilus influenzae type b infection, cost-effectiveness analysis, cost-utility analysis, budget impact analysis